Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Prevention, Genetics
Results 1-25 of 146 for your search:
Start Over
Behavioral Counseling and Nicotine Replacement Therapy or Varenicline in Helping Smokers Quit
Status: Active
Phase: Phase IV
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Age: 18 to 65
Trial IDs: 2014-0207, NCI-2014-01485, NCT02162849
Varenicline and Nicotine Replacement Therapy for Initial Smoking Cessation and Treatment in Smokers
Status: Active
Phase: Phase IV
Type: Behavioral study, Prevention
Age: 18 to 65
Trial IDs: 2014-0213, NCI-2015-00610, NCT02271919
Informing Tobacco Treatment Guidelines for African American Non-Daily Smokers
Status: Active
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: STUDY00001602, NCI-2015-01331, AD-1310-08709, NCI-2015-00937, NCT02244918
Proactive Counseling and Nicotine Replacement Therapy in Changing the Default for Tobacco Treatment in Smokers
Status: Enrolling by invitation
Phase: Phase IV
Type: Prevention, Supportive care
Age: 18 and over
Trial IDs: STUDY00001774, NCI-2016-01534, NCT02721082
68Ga-RM2 PET/MRI in Detecting Prostate Cancer in Patients with Biochemical Recurrent and CT Scan Negative Prostate Cancer
Status: Active
Phase: Phase III, Phase II
Type: Genetics
Age: 18 and over
Trial IDs: PROS0074, NCI-2015-01993, 348, NCT02624518
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients with Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: GOG-0225, NCI-2009-00595, CDR0000594600, NCT00719303
Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Status: Active
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: S0820, NCI-2012-02067, SWOG-S0820, NCT01349881
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)
Status: Active
Phase: Phase III
Type: Prevention
Age: 15 and over
Trial IDs: GHRT01, NCI-2014-02097, NCT01479283
Metformin Hydrochloride in Preventing Breast Cancer in Patients with Atypical Hyperplasia or In Situ Breast Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 25 to 55
Trial IDs: A211102, NCI-2013-00995, CALGB-A211102, NCT01905046
Topical or Ablative Treatment in Preventing Anal Cancer in Patients with HIV and Anal High-Grade Squamous Intraepithelial Lesions
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention
Age: 35 and over
Trial IDs: AMC-A01, NCI-2014-00636, NCT02135419
Varenicline for Adolescent Smoking Cessation
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 14 to 21
Trial IDs: Pro00014398, NCI-2016-02034, NCT01509547
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
Status: Active
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: CR107047, NCI-2016-00410, 2015-001630-21, 39039039STM4001, NCT02555878
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Not yet active
Phase: Phase III
Type: Prevention, Supportive care, Treatment
Age: 2 to 25
Trial IDs: ACCL1633, NCI-2017-00208, COG-ACCL1633, NCT03057054
Apixaban in Preventing Secondary Cancer Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy
Status: Not yet active
Phase: Phase III
Type: Prevention, Supportive care
Age: 18 and over
Trial IDs: ACCRU-SC-1601, NCI-2017-00325, NCT03080883
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
Status: Not yet active
Phase: Phase III
Type: Prevention, Treatment
Age: 18 to 70
Trial IDs: CR-AIR-009, NCI-2017-01213, 2016-004672-21, NCT02999854
Palifermin in Preventing Graft-versus-Host Disease in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Prevention
Age: 18 to 70
Trial IDs: 15-C-0067, NCI-2015-00084, P131448, NCT02356159
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients with Hematologic Malignancies Undergoing HSCT
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Age: 3 to 30
Trial IDs: PEDSBMT295, NCI-2016-00387, NCT02728700
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Prevention
Age: 18 to 70
Trial IDs: PT-001, NCI-2016-00907, NCT02743351
Azacitidine and Cyclophosphamide after Donor Stem Cell Transplantation in Preventing GVHD in Patients with Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Advanced Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Prevention, Treatment
Age: 18 and over
Trial IDs: 201604081, NCI-2016-00582, NCT02750254
Pacritinib, Sirolimus, and Tacrolimus in Preventing Graft Versus Host Disease in Patients with Blood Cancer Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Prevention, Supportive care
Age: 18 and over
Trial IDs: MCC-18783, NCI-2017-00594, NCT02891603
Novel Determinants and Measures of Smokeless Tobacco Use: Study 2
Status: Active
Phase: Phase II
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 1R01CA141531-01, NCI-2016-00485, 1R01CA141531, NCT01067599
Vandetanib in Preventing Head and Neck Cancer in Patients with Precancerous Head and Neck Lesions
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 11-0265, NCI-2011-01246, NCT01414426
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention
Age: 9 to 26
Trial IDs: X141204010, NCI-2011-03654, 000508488, 113426, F141204009, XUAB14102, NCT01492582
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD after Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients with Hematological Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 0 to 75
Trial IDs: 2546.00, NCI-2011-03828, NCT01527045
Breast-Conserving Surgery and Radiation Therapy in Treating Patients with Multiple Ipsilateral Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 40 and over
Trial IDs: Z11102, NCI-2012-00707, ACOSOG-Z11102, CDR0000728605, NCT01556243
Start Over